MAPT and Alzheimer disease: In AD and related dementias, total tau and phosphorylated tau (t- and p-tau, respectively) in fluids are significantly higher compared with healthy controls, and correlate with the cognitive decline of patients, with very high levels of t-tau and p-tau in CSF predicting poor clinical outcomes [41–43].